tiprankstipranks
Trending News
More News >
STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Advertisement

STRATEC Biomedical (SBS) AI Stock Analysis

Compare
5 Followers

Top Page

DE:SBS

STRATEC Biomedical

(XETRA:SBS)

Select Model
Select Model
Select Model
Neutral 59 (OpenAI - 4o)
Rating:59Neutral
Price Target:
€28.00
▲(4.87% Upside)
STRATEC Biomedical's overall stock score reflects a mixed financial performance and bearish technical indicators. The company's fair valuation provides some support, but declining financial metrics and negative market momentum are significant concerns.

STRATEC Biomedical (SBS) vs. iShares MSCI Germany ETF (EWG)

STRATEC Biomedical Business Overview & Revenue Model

Company DescriptionSTRATEC Biomedical (SBS) is a leading company in the field of biomedical engineering, specializing in the development and manufacturing of automated laboratory systems and diagnostic instruments. The company operates primarily in the healthcare sector, providing innovative solutions for in-vitro diagnostics, including a wide range of analyzers, consumables, and software. STRATEC's products are designed to enhance laboratory efficiency and improve the quality of patient care, serving a global customer base that includes diagnostic companies and laboratories.
How the Company Makes MoneySTRATEC Biomedical generates revenue through multiple streams, primarily by providing automated diagnostic systems and associated consumables to healthcare organizations and laboratories. The company earns money from the sales of its proprietary analyzers and instruments, which are often sold in partnership with major diagnostic companies that utilize STRATEC's technology in their own products. Additionally, STRATEC benefits from recurring revenue through the sale of consumables that are required for the operation of its diagnostic systems. The company also engages in long-term contracts and collaborations with partners, which can include joint development projects and technology licensing agreements, further contributing to its revenue. Overall, STRATEC's business model is built on providing high-quality, reliable solutions that enable its customers to improve diagnostic processes and patient outcomes.

STRATEC Biomedical Financial Statement Overview

Summary
STRATEC Biomedical shows a mixed financial performance with stable gross profit margins but declining net profit margins and revenue. The balance sheet indicates moderate financial stability with a manageable debt-to-equity ratio. However, significant reductions in free cash flow highlight potential liquidity issues.
Income Statement
STRATEC Biomedical's income statement shows a mixed performance. The company has a stable gross profit margin of around 29.65% in TTM, indicating efficient production processes. However, the net profit margin has decreased to 6.22% in TTM, reflecting challenges in controlling costs or pricing strategies. Revenue has declined by 3.35% in TTM, suggesting potential market or competitive pressures. The EBIT and EBITDA margins are relatively healthy at 10.83% and 18.38%, respectively, but have shown a downward trend, indicating potential operational inefficiencies.
Balance Sheet
The balance sheet of STRATEC Biomedical reflects moderate financial stability. The debt-to-equity ratio stands at 0.54 in TTM, which is manageable but indicates a reliance on debt financing. The return on equity has decreased to 6.23% in TTM, suggesting reduced profitability for shareholders. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets, indicating a solid capital structure.
Cash Flow
STRATEC Biomedical's cash flow statement reveals some concerns. The free cash flow has significantly decreased by 59.31% in TTM, highlighting potential liquidity issues. The operating cash flow to net income ratio is 0.54, indicating that cash generation from operations is not fully covering net income. The free cash flow to net income ratio is 0.63, suggesting that the company is not generating sufficient free cash flow relative to its net income, which could impact future investments or debt repayments.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue257.14M257.62M270.41M274.63M287.33M250.10M
Gross Profit77.96M76.39M68.16M79.49M87.71M68.99M
EBITDA45.08M47.34M43.16M57.53M66.52M56.72M
Net Income14.70M16.02M15.37M29.22M39.96M25.18M
Balance Sheet
Total Assets422.41M445.06M466.58M397.50M368.52M331.90M
Cash, Cash Equivalents and Short-Term Investments18.70M48.73M34.22M24.07M48.72M39.15M
Total Debt128.70M130.53M141.37M87.15M85.30M109.58M
Total Liabilities185.71M202.53M233.25M172.32M162.77M159.36M
Stockholders Equity236.70M242.53M233.33M225.18M205.76M172.54M
Cash Flow
Free Cash Flow10.98M30.52M2.00M-8.74M43.24M6.27M
Operating Cash Flow25.56M48.71M19.43M10.28M63.47M31.85M
Investing Cash Flow-16.16M-15.97M-44.16M-19.00M-20.13M-21.84M
Financing Cash Flow-21.09M-20.30M35.44M-14.11M-34.33M5.22M

STRATEC Biomedical Technical Analysis

Technical Analysis Sentiment
Negative
Last Price26.70
Price Trends
50DMA
27.95
Negative
100DMA
27.28
Negative
200DMA
27.30
Negative
Market Momentum
MACD
-0.16
Positive
RSI
39.40
Neutral
STOCH
39.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SBS, the sentiment is Negative. The current price of 26.7 is below the 20-day moving average (MA) of 29.22, below the 50-day MA of 27.95, and below the 200-day MA of 27.30, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 39.40 is Neutral, neither overbought nor oversold. The STOCH value of 39.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SBS.

STRATEC Biomedical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
€1.06B28.8717.61%0.94%9.42%9.54%
64
Neutral
€1.26B14.536.87%2.62%-0.03%-14.15%
59
Neutral
€350.09M20.712.25%-1.64%22.60%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
€1.31B64.150.11%-18.82%-113.85%
49
Neutral
€49.38M-3.55-111.86%-4.90%-69.80%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:SBS
STRATEC Biomedical
26.70
-11.47
-30.06%
DE:BIO
Biotest
38.00
-3.60
-8.65%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.22
-0.28
-11.20%
DE:DRW3
Draegerwerk AG & Co. KGaA
77.40
32.13
70.99%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
17.66
3.27
22.68%
DE:PUS
Pulsion Medical Systems
21.20
5.90
38.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2025